Samvat 2081: SBI, ITC, Titan, Jyothy Labs among Religare’s top stock picks for Diwali 2024

Religare Broking has picked a total of five stocks for Samvat 2081. The brokerage house has selected SBI, ITC, Titan Company, Berger Paints India, and Jyothy Labs. The brokerage firm has given the rationale behind these stocks. 

State Bank of India

State Bank of India (SBI), India’s largest public sector bank, holds a strong 22-23% market share in credit. With consistent loan growth across retail, corporate, and SME sectors, it benefits from a stable deposit base and funding advantage. SBI’s strong internal accruals, leadership in term deposits, and efficient credit management position it well for future growth, especially with an expected revival in corporate capex.

Well-positioned in terms of LDR, LCR, SA and regulatory deposits: In the current environment of constrained credit growth due to high loan-to-deposit ratios (LDR), SBI is well-positioned with a low domestic LDR of 69%. While its deposit growth is softer than the system average, the low LDR makes this less of a concern. SBI holds a high share of stable retail deposits and has minimal run-offs, giving it the flexibility to use bulk deposits if needed. Despite offering lower savings account rates than private peers, SBI maintains a high SA share and leads in term deposit pricing, though it needs to improve its current account share and fee income. Could gain market share as peers struggle: Unlike other PSU banks, SBI has maintained a steady credit market share of 22-23%, with consistent loan growth across SME, retail, and corporate segments. It stands to benefit from a corporate capex revival. Although overall loan growth is slowing, SBI is well-positioned to gain market share due to its improved credit delivery, funding advantage, and challenges at its nearest competitor. With strong internal accruals and reasonable CET 1, raising fresh capital would further enhance its growth prospects. Technology investments drive cost efficiency: Over the years investment in technology has been instrumental in bringing its cost-to-income ratio below 50%.

SBI is well-positioned with a low loan-to-deposit ratio, allowing flexibility despite softer deposit growth. Its stable retail deposits and consistent 22-23% credit market share enable it to gain market share as competitors struggle. Additionally, technology investments have improved cost efficiency, reducing the cost-to-income ratio below 50% and enhancing long-term profitability. Based on these factors, we expect NII/ PPOP/PAT to grow at a CAGR of 14.2%/7.6%/7% over FY24-26E. We have a “Buy” rating on the bank with a target price of Rs 941.

 » Read More

Related Articles

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain

Range bound session: Nifty ends above 23,600, Sensex holds 78,000 led by Adani Ports, Infosys

The stock markets faced a downturn on Thursday, with major indices closing in the red. The BSE Sensex dropped by 213.12 points or 0.27%, ending the day at 78,058.16, while the NSE Nifty 50 saw a decline of 70.15 points, down by 0.3%, and closed at 23,626.15. The Nifty Bank index also ended the day

IT stocks stable as Cognizant raises annual and quarterly revenue guidance

Shares of Indian IT companies are in the spotlight today after the Nasdaq-listed IT services major Cognizant Technology Solutions, reported its Q4 results that exceeded Wall Street expectations. The Nifty IT Index as well as individual tech counters like Infosys, Wipro, Tech Mahindra and HCL Tech are all in the green even as the markets